PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26915800-7 2016 We also found that the effects of APS on upregulating hepcidin and IL-6 expressions could be antagonized by pretreatment with SB203580, an inhibitor of p38 MAPK signaling. SB 203580 126-134 interleukin 6 Homo sapiens 67-71 28794655-10 2017 Further evidence indicated that P2Y12 and P2Y13 receptor-evoked increased gene expression of IL-1beta, IL-6 and TNF-alpha were inhibited by Y-27632 (ROCK inhibitor), SB203580 (P38MAPK inhibitor) and PDTC (NF-kappab inhibitor), respectively. SB 203580 166-174 interleukin 6 Homo sapiens 103-107 28794655-11 2017 Subsequently, P2Y12 and P2Y13 receptor-evoked release of IL-1beta, IL-6 and TNF-alpha, were also inhibited by Y-27632, SB203580 and PDTC, respectively. SB 203580 119-127 interleukin 6 Homo sapiens 67-71 28730070-8 2017 Various signal pathway inhibitors, including SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and BAY11-7082 (NF-kappaB inhibitor) significantly decreased the UVB-induced secretion of IL-6 and IL-8 secretion (P<0.05). SB 203580 71-79 interleukin 6 Homo sapiens 191-195 27650973-7 2016 NE-induced IL-6 was significantly inhibited by p38 inhibitor, SB203580, suggesting that NE-induced phosphorylation of p38 via ARbeta enhances IL-6 production in SSc fibroblasts. SB 203580 62-70 interleukin 6 Homo sapiens 11-15 27650973-7 2016 NE-induced IL-6 was significantly inhibited by p38 inhibitor, SB203580, suggesting that NE-induced phosphorylation of p38 via ARbeta enhances IL-6 production in SSc fibroblasts. SB 203580 62-70 interleukin 6 Homo sapiens 142-146 27394658-6 2016 p38 and ERK1/2 MAPKs were involved in this effect, as indicated by the Cry1Ac-induced upregulation of CD80 and IL-6 and TNF-alpha abrogation by the p38 MAPK inhibitor SB203580. SB 203580 167-175 interleukin 6 Homo sapiens 111-115 28465707-7 2017 The downmodulation of IL-6 by P. cicadae was inhibited by the p38 inhibitor (SB203580) or JNK inhibitor (SP600125). SB 203580 77-85 interleukin 6 Homo sapiens 22-26 27995982-10 2016 P38 inhibitor SB203580 suppressed IL-6 production, and inhibition of IL-6 receptor (IL-6R) activation by tocilizumab suppressed Fos expression. SB 203580 14-22 interleukin 6 Homo sapiens 34-38 25515776-9 2015 The production of IL6 and IL8 was also suppressed by p38 inhibitor SB203580. SB 203580 67-75 interleukin 6 Homo sapiens 18-21 25715004-7 2015 The latanoprost-induced release of IL-6, IL-8, and MCP-1 was attenuated by inhibitors of MAPK (PD98059, SB203580, or JNK inhibitor II) or NF-kappaB (IkappaB kinase 2 inhibitor) signaling pathways. SB 203580 104-112 interleukin 6 Homo sapiens 35-39 25849622-11 2015 IL-6 expression was more sensitive to inhibition of p38 (using SB203580) and was affected by Stattic in response to IL-17A/OSM stimulation. SB 203580 63-71 interleukin 6 Homo sapiens 0-4 22605923-6 2012 Pretreatment with 10(-10) M 17-beta-estradiol greatly inhibited the increased expression and production of IL-6, IL-1, and TNF-alpha induced by hyperosmolarity, whereas with the administration of SB203580 (10 muM), an inhibitor of the p38 pathway, the inhibiting effect of 17-beta-estradiol disappeared. SB 203580 196-204 interleukin 6 Homo sapiens 107-111 25239226-6 2015 Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580. SB 203580 92-100 interleukin 6 Homo sapiens 13-17 25239226-6 2015 Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580. SB 203580 200-208 interleukin 6 Homo sapiens 13-17 25239226-8 2015 Results showed that IL-6 promoter activity of the parent pIL-6-Luc651 was significantly enhanced by IL-1beta, but the level was significantly attenuated by SB203580. SB 203580 156-164 interleukin 6 Homo sapiens 20-24 21979577-8 2012 SB203580 inhibited ATP-induced TNF-alpha, IL-6, and NO production. SB 203580 0-8 interleukin 6 Homo sapiens 42-46 21161531-6 2012 Furthermore, IL-6 and IL-8 expression was quantified by real-time polymerase chain reaction (RT-PCR) and ELISAs from cells which were exposed to SB203580, U0126 and NaHS and stimulated by IL-1beta. SB 203580 145-153 interleukin 6 Homo sapiens 13-17 24954857-12 2014 The p38-MAPK inhibitor SB203580 abolished the IL-6-induced WNT5A up-regulation and blocked IL-6-induced melanoma cell invasion. SB 203580 23-31 interleukin 6 Homo sapiens 46-50 24954857-12 2014 The p38-MAPK inhibitor SB203580 abolished the IL-6-induced WNT5A up-regulation and blocked IL-6-induced melanoma cell invasion. SB 203580 23-31 interleukin 6 Homo sapiens 91-95 24995301-1 2014 The study was designed to determine the effects of peripheral injection of SB203580 on the synthesis of interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the hypothalamus of ewes during prolonged inflammation. SB 203580 75-83 interleukin 6 Homo sapiens 130-134 24995301-3 2014 SB203580 is a selective ATP-competitive inhibitor of the p38 mitogen-activated protein kinase (MAPK), which is involved in the regulation of proinflammatory cytokines IL-1beta, IL-6 and TNFalpha synthesis. SB 203580 0-8 interleukin 6 Homo sapiens 177-181 24995301-4 2014 Intravenous injection of SB203580 successfully inhibited (P < 0.01) synthesis of IL-1beta and reduced (P < 0.01) the production of IL-6 in the hypothalamus. SB 203580 25-33 interleukin 6 Homo sapiens 137-141 23219088-6 2013 UVB-induced production of IL-6 was inhibited by SB203580, a p38 MAPK inhibitor. SB 203580 48-56 interleukin 6 Homo sapiens 26-30 23232207-8 2013 CAP-induced time dependent changes in the phosphorylation status of mitogen activated protein kinase (MAPK) signaling mediators that led to a 2.5-fold increase in IL-6 release after 24 h. This rise did not occur either in TRPV1 siRNA gene silenced cells or during exposure to SB203580 (10 muM), a selective p38 MAPK inhibitor. SB 203580 276-284 interleukin 6 Homo sapiens 163-167 24302816-7 2013 Furthermore, both NF- kappa B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. SB 203580 69-77 interleukin 6 Homo sapiens 130-134 22110547-7 2012 In addition, EBNE-induced production of IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-kappaB inhibitor), but not SP600125 (a JNK inhibitor). SB 203580 106-114 interleukin 6 Homo sapiens 40-44 22129063-6 2011 U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF. SB 203580 43-51 interleukin 6 Homo sapiens 111-115 21288261-5 2011 Using two potent and selective inhibitors of MEK activation by Raf-1 (PD-098059) and p38 (SB-203580), it was also demonstrated that both ERK1/2 and p38 pathways play key roles in the production of IL-6 as well as in ICAM-1, VCAM-1 and E-selectin expression by Hib porin. SB 203580 90-99 interleukin 6 Homo sapiens 197-201 21176394-7 2011 The IL-6 secretory pathway of MSCs was inhibited by SB203580, an inhibitor of p38 MAPK or siRNA against p38 MAPK, suggesting IL-6 secretion by MSCs is mediated through the activation of p38 MAPK. SB 203580 52-60 interleukin 6 Homo sapiens 4-8 20739465-10 2011 Hypertonicity-induced increases in IL-6 and IL-8 releases were suppressed by exposure to capsazepine, AG 1478, ERK inhibitor PD 98059, p38 inhibitor SB 203580, or NF-kappaB inhibitor PDTC. SB 203580 149-158 interleukin 6 Homo sapiens 35-39 21176394-7 2011 The IL-6 secretory pathway of MSCs was inhibited by SB203580, an inhibitor of p38 MAPK or siRNA against p38 MAPK, suggesting IL-6 secretion by MSCs is mediated through the activation of p38 MAPK. SB 203580 52-60 interleukin 6 Homo sapiens 125-129 20631726-6 2010 EGFP-LEDGF-HaCaT cells had increased expression of IL-6, which was attenuated by LEDGF-specific RNA interference and the p38-specific inhibitors SB-239063 and SB-203580. SB 203580 159-168 interleukin 6 Homo sapiens 51-55 20351184-6 2010 The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression. SB 203580 81-89 interleukin 6 Homo sapiens 127-131 20351184-6 2010 The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression. SB 203580 81-89 interleukin 6 Homo sapiens 145-149 19656660-12 2009 Distinctly, pharmacological inhibition of p38 MAPK with SB203580 was associated with transcriptional down-regulation of COX-2 and MMP-13 in the IL-1beta- or PMA-treated HSF cells. SB 203580 56-64 interleukin 6 Homo sapiens 169-172 19931737-8 2009 The p38 inhibitor SB203580, by blocking nuclear factor-kappaB (NF-kappaB) activation, prevented both the transcriptional and translational regulation of radiation-induced IL-6 expression. SB 203580 18-26 interleukin 6 Homo sapiens 171-175 19576293-10 2009 As intracellular signalling pathway we could demonstrate that SB203580 as specific p38 inhibitor most effectively down regulated the unwanted IL-6 release after cooling and rewarming. SB 203580 62-70 interleukin 6 Homo sapiens 142-146 18825409-9 2009 Pretreatment of cells with SB203580 (inhibitor of p38) and PD98059 (inhibitor of ERK) attenuated LPS-induced IL-6 expression, whereas LY294002 (inhibitor of PI3K) markedly amplified the LPS-stimulated synthesis of IL-6. SB 203580 27-35 interleukin 6 Homo sapiens 109-113 18825409-9 2009 Pretreatment of cells with SB203580 (inhibitor of p38) and PD98059 (inhibitor of ERK) attenuated LPS-induced IL-6 expression, whereas LY294002 (inhibitor of PI3K) markedly amplified the LPS-stimulated synthesis of IL-6. SB 203580 27-35 interleukin 6 Homo sapiens 214-218 18457971-5 2008 p38 MAPK inhibitor SB203580 suppressed interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release, as well as the activation of cPLA(2). SB 203580 19-27 interleukin 6 Homo sapiens 72-85 19249598-5 2009 A p38 mitogen-activated protein kinase inhibitor, SB203580, also inhibited the increase in IL-6 messenger RNA levels. SB 203580 50-58 interleukin 6 Homo sapiens 91-95 19494504-11 2009 Eotaxin-induced production of IL-1beta, IL-6, and MIP-1beta was significantly reduced by the MEK inhibitor PD98059, p38 MAPK inhibitor SB203580, or PI3K inhibitor LY294002. SB 203580 135-143 interleukin 6 Homo sapiens 40-44 18457971-5 2008 p38 MAPK inhibitor SB203580 suppressed interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release, as well as the activation of cPLA(2). SB 203580 19-27 interleukin 6 Homo sapiens 87-91 18457971-8 2008 As a downstream enzyme of cPLA(2), cyclooxygenase-2 (COX-2) was down-regulated by SB203580 and/or AACOCF(3), which precisely matched the levels of IL-1beta and IL-6. SB 203580 82-90 interleukin 6 Homo sapiens 160-164 17724435-10 2008 SB203580 also prevented the CytoMix-induced permeability increase and reduced NO, IL-6, and IL-8 levels. SB 203580 0-8 interleukin 6 Homo sapiens 82-86 18093851-6 2008 SB-203580 caused dose-dependent decreases in cytokine protein expression and decreased IL-6 and IL-11 mRNA expression. SB 203580 0-9 interleukin 6 Homo sapiens 87-91 15913932-6 2005 SB203580 inhibited the expression of IL-6 mRNA. SB 203580 0-8 interleukin 6 Homo sapiens 37-41 18177344-6 2008 However, p38 inhibitor SB203580 abrogated TNF-alpha, IL-1beta and IL-6 production. SB 203580 23-31 interleukin 6 Homo sapiens 66-70 17876544-10 2007 Inhibitors for ERK (PD98059 and U0216) and p38 MAPK (SB203580) significantly reduced the IL-17F-induced IL-6, IL-8, LIF, MMP-1, and MMP-3 secretion. SB 203580 53-61 interleukin 6 Homo sapiens 104-108 17637508-11 2007 AG490 as well as SB 203580 and parthenolide blocked CT-1 induced IL-6 expression completely. SB 203580 17-26 interleukin 6 Homo sapiens 65-69 17196171-5 2007 Furthermore, IL-6 secretion by PC-3 and DU145 cells was significantly suppressed by SAPKs inhibitor, especially by p38MAPK inhibitor SB203580, but not by JNK inhibitor SP600125 nor by MEK inhibitor, PD98059. SB 203580 133-141 interleukin 6 Homo sapiens 13-17 17849265-5 2007 When added to MG-63 cells, IL-6 stimulated the production of cathepsin B, which was reduced significantly by the addition of SB203580, a specific p38 MAPK inhibitor. SB 203580 125-133 interleukin 6 Homo sapiens 27-31 17849265-10 2007 Moreover, IL-6 increased the activity of urokinase type plasminogen activator (uPA) in MG-63 cells, which was inhibited by SB203580, PDTC and NF-kappaB SN50. SB 203580 123-131 interleukin 6 Homo sapiens 10-14 17207362-4 2007 RESULTS: SB203580 obviously down-regulated the activities of p38 and cPLA(2), as well as the release of IL-1 beta and IL-6. SB 203580 9-17 interleukin 6 Homo sapiens 118-122 16532021-6 2006 The p38 inhibitor SB203580 and the PKC inhibitors Calphostin C and Go6976 completely inhibited IL-1-induced IL-6 production. SB 203580 18-26 interleukin 6 Homo sapiens 108-112 15894558-8 2005 SB-203580, a p38 MAPK-specific inhibitor, inhibits IL-6-induced p38 MAPK phosphorylating activity and suppresses IL-6-stimulated cell proliferation. SB 203580 0-9 interleukin 6 Homo sapiens 51-55 15894558-8 2005 SB-203580, a p38 MAPK-specific inhibitor, inhibits IL-6-induced p38 MAPK phosphorylating activity and suppresses IL-6-stimulated cell proliferation. SB 203580 0-9 interleukin 6 Homo sapiens 113-117 18292576-8 2008 SB203580 inhibited the phosphorylation of c-Fos enhanced by IL-1 plus IL-6, and diminished expression of the CRP gene. SB 203580 0-8 interleukin 6 Homo sapiens 70-74 17845838-4 2008 We found that pre-treatment of microglial cells with a p38-inhibitor (SB203580) prevented Mn+LPS-induced production of IL-6 and TNF-alpha. SB 203580 70-78 interleukin 6 Homo sapiens 119-123 17197193-11 2006 AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression. SB 203580 7-15 interleukin 6 Homo sapiens 82-86 16197469-7 2005 NF-kappaB inhibitor BAY 11-7082 and p38 MAPK inhibitor SB 203580 significantly decreased IL-6 release in a co-culture of BEAS-2B cells and eosinophils. SB 203580 55-64 interleukin 6 Homo sapiens 89-93 15917303-5 2005 Pretreatment with the pharmacological inhibitors of p38 MAPK SB-203580 or SB-202190 blocked IL-6-induced SGK phosphorylation at Ser78 and SGK activation. SB 203580 61-70 interleukin 6 Homo sapiens 92-96 15913932-5 2005 Increased IL-6 by DFX was significantly inhibited by p38 inhibitor, SB203580 (about 72% inhibition, P=0.027) but not ERK inhibitor, PD98059 or JNK inhibitor, SP600125. SB 203580 68-76 interleukin 6 Homo sapiens 10-14 16435581-2 2005 When added to HGFs, IL-1beta had a stimulatory effect on the production of IL-6, and this effect was significantly reduced by SB203580, a specific p38 MAPK inhibitor. SB 203580 126-134 interleukin 6 Homo sapiens 75-79 15796767-9 2005 The LPS-induced IL-6 production was blocked by the specific p38alphaMAP kinase inhibitor, SB203580, and by the synthetic glucocorticoid, dexamethasone. SB 203580 90-98 interleukin 6 Homo sapiens 16-20 16435581-4 2005 Both the NF-kappaB inhibitors in the presence of SB203580 had more inhibitory effect on IL-6 release. SB 203580 49-57 interleukin 6 Homo sapiens 88-92 12637577-2 2003 Here we show unequivocally that the production of interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor alpha (TNFalpha) requires p38 MAPK activity by demonstrating that the inhibitory effects of SB 203580 were reversed by expression of an SB 203580-resistant form of p38alpha (SBR-p38alpha) that fails to bind to SB 203580. SB 203580 205-214 interleukin 6 Homo sapiens 74-78 15251176-9 2004 When cells exposed to 200 microM SM were treated with the p38 MAP kinase inhibitor SB203580, the levels of IL-8, IL-6, and TNF-alpha and IL-1beta were significantly decreased when compared with cells that were untreated. SB 203580 83-91 interleukin 6 Homo sapiens 113-117 14565941-9 2004 Activation of p38 MAPK was also seen in cocultures by Western blot, whereas IL-6 production in cocultures was significantly inhibited by the p38 inhibitor SB203580. SB 203580 155-163 interleukin 6 Homo sapiens 76-80 15345683-11 2004 The addition of SB203580 to ionomycin decreased (P<0.05) nuclear p-p38 MAPK and totally abolished (P<0.05) the ionomycin- induced increase in IL-6 mRNA. SB 203580 16-24 interleukin 6 Homo sapiens 148-152 15345332-6 2004 Furthermore, both SB203580 (an inhibitor of p38 mitogen-activated protein kinase [MAPK]) and PD98059 (an inhibitor of MEK, upstream of ERK) attenuated the BK-induced IL-6 and PGE(2) synthesis. SB 203580 18-26 interleukin 6 Homo sapiens 166-170 15117678-6 2004 Expression of IL-1beta, IL-6, IL-8, and COX-2 mRNA was reduced by 30 microM PP1, an Src family tyrosine kinase inhibitor, and by 25 microM SB-203580, a p38 MAPK inhibitor. SB 203580 139-148 interleukin 6 Homo sapiens 24-28 14998552-7 2004 SB203580 and PD98059 decreased LPS-induced gene expression of IL-1beta and IL-6. SB 203580 0-8 interleukin 6 Homo sapiens 75-79 12853969-6 2003 IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6. SB 203580 137-145 interleukin 6 Homo sapiens 0-4 12145097-7 2002 SB203580 decreased IL-6 production and gene expression, but PD98059 had no effect on IL-6 production and gene expression. SB 203580 0-8 interleukin 6 Homo sapiens 19-23 12505790-3 2003 Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect. SB 203580 33-42 interleukin 6 Homo sapiens 167-171 12594059-8 2003 Blocking ERK1/2 with PD98059 or p38 MAPK with SB203580 reduced BK-induced IL-6 expression. SB 203580 46-54 interleukin 6 Homo sapiens 74-78 12137744-5 2002 The inhibitors SB203580, PD98059, SN50, cycloheximide and D-ribofuranosylbenzimidazole each reduced the basal and TNFalpha-stimulated secretion of IL-1beta and also reduced IL-6 secretion with the exception of SN50. SB 203580 15-23 interleukin 6 Homo sapiens 173-177 11319753-5 2001 SB 203580, a selective inhibitor of p38 MAPK, inhibited IL-1 and TNF-induced p38 MAPK activity and IL-6 production (IC(50)s 0.3--0.5 microM) in osteoblasts and chondrocytes. SB 203580 0-9 interleukin 6 Homo sapiens 99-103 12008923-4 2002 The p38 inhibitor SB 203580 also suppressed their IL-6 production-inducing activities, whereas the ERK1/2-activating MAPK kinase (MEK1) inhibitor PD 98059 did not suppress their activities. SB 203580 18-27 interleukin 6 Homo sapiens 50-54 11747626-6 2001 In human osteoblasts (SaM-1 cells) treated with 10 microg/ml LPS, increases in IL-6 mRNA and synthesis were inhibited by anti-CD14 antibody (MEM-18), PD98059 (an inhibitor of classic mitogen-activated protein kinase [MAPK]), or SB203580 (an inhibitor of p38 MAPK) but were not inhibited by H-89 (an inhibitor of protein kinase A [PKA]) and calphostin C (an inhibitor of protein kinase C [PKC]). SB 203580 228-236 interleukin 6 Homo sapiens 79-83 11597988-8 2001 PD98059 and SB203580 inhibited Ang II-induced IL-6 expression. SB 203580 12-20 interleukin 6 Homo sapiens 46-50 12016129-9 2002 MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion. SB 203580 17-26 interleukin 6 Homo sapiens 90-94 12020969-6 2002 Interestingly, SB203580 reduced the mRNA expression for iNOS, TNFalpha, and IL-6, indicating inhibition prior to translation. SB 203580 15-23 interleukin 6 Homo sapiens 76-80 11562425-3 2001 Pretreatment of ASM cells with SB203580, a p38 MAPK inhibitor, slightly enhanced TNF alpha-induced ICAM-1 expression in a dose-dependent manner but partially inhibited secretion of RANTES and IL-6. SB 203580 31-39 interleukin 6 Homo sapiens 192-196 11165942-2 2001 When added to MG-63 cells, tumor necrosis factor-alpha (TNF-alpha) had a stimulatory effect on the production of IL-6, and this elevation was significantly reduced by SB203580, a specific p38 MAPK inhibitor. SB 203580 167-175 interleukin 6 Homo sapiens 113-117 11231289-3 2001 Pharmacologic inhibition of either the ERK or the p38 MAPK pathway, using U0126 and SB203580, respectively, reduced interleukin-6 protein induction by at least 70%, and combined inhibition of both pathways fully blocked interleukin-6 protein expression and reduced interleukin-6 mRNA induction by more than 80%. SB 203580 84-92 interleukin 6 Homo sapiens 116-129 11401420-4 2001 The p38 MAPK pathway is specifically involved in the combined agents-induced NO and IL-6 release, since NO and IL-6 release in the presence of a specific inhibitor of p38 MAPK, 4-(4-fluorophenyl)-2-(4-metylsulfinylphenyl)-5-(4-pyridyl)imidazole (SB203580), are significantly diminished. SB 203580 246-254 interleukin 6 Homo sapiens 84-88 11165942-4 2001 Both the NF-kappaB inhibitors in the presence of SB203580 had a more inhibitory effect on IL-6 release. SB 203580 49-57 interleukin 6 Homo sapiens 90-94 12760489-2 2001 When added to cultures of cardiomyocytes, the combined agents (LPS/IFN-gamma or TNF-alpha/IFN-gamma) had stimulatory effect on the production of IL-6 and the elevation was significantly reduced by SB203580, a specific p38 MAPK inhibitor. SB 203580 197-205 interleukin 6 Homo sapiens 145-149 12760489-3 2001 SB203580 inhibited protein production and gene expression of IL-6 in a concentration-dependent manner. SB 203580 0-8 interleukin 6 Homo sapiens 61-65 10873157-5 2000 Expression of IL-6 and IL-8 was sensitive to SB203580, the specific inhibitor of p38 mitogen-activated protein (MAP) kinase and PD98059, an inhibitor of MAP kinase kinase. SB 203580 45-53 interleukin 6 Homo sapiens 14-18 11028659-8 2000 Furthermore, PD98059 or SB203580 significantly suppressed BK-induced IL-6 and IL-8 production and their gene expression. SB 203580 24-32 interleukin 6 Homo sapiens 69-73 10734320-6 2000 A pyrimidazole compound, SB203580, a specific inhibitor of p38 MAPK, inhibits production and gene expression of IL-6. SB 203580 25-33 interleukin 6 Homo sapiens 112-116 10727406-6 2000 Furthermore, inhibition of p38 kinase activity with the inhibitor SB203580 did not block STAT3 Ser(727) phosphorylation but rather increased both basal as well as IL-6-induced STAT3 transactivation, indicating that p38 may act as a negative regulator of IL-6-induced STAT3 transactivation through a presently unknown mechanism. SB 203580 66-74 interleukin 6 Homo sapiens 163-167 10727406-6 2000 Furthermore, inhibition of p38 kinase activity with the inhibitor SB203580 did not block STAT3 Ser(727) phosphorylation but rather increased both basal as well as IL-6-induced STAT3 transactivation, indicating that p38 may act as a negative regulator of IL-6-induced STAT3 transactivation through a presently unknown mechanism. SB 203580 66-74 interleukin 6 Homo sapiens 254-258 10734320-7 2000 SB203580 reduced significantly the stability of IL-6 mRNA. SB 203580 0-8 interleukin 6 Homo sapiens 48-52 10504489-11 1999 The role of these activations in IL-6 production was confirmed by the ability of both inhibitors SB203580 (1 to 30 microM) and PD98059 (0.01 to 10 microM) to inhibit basal and TNF-alpha-stimulated IL-6 production in both cell types. SB 203580 97-105 interleukin 6 Homo sapiens 33-37 10620700-2 2000 Pretreatment of RSF with a specific p38 MAP kinase inhibitor, SB203580, blocked the induction of IL-6 and IL-8 without affecting nuclear translocation of nuclear factor kappaB (NF-kappaB) or IL-6 and IL-8 mRNA levels. SB 203580 62-70 interleukin 6 Homo sapiens 97-101 10586114-7 1999 The IL-1-enhanced IL-6 protein secretion was strongly reduced by SB203580 and PD98059. SB 203580 65-73 interleukin 6 Homo sapiens 18-22 10534331-10 1999 Selective inhibition of either the p44/p42 MAPK pathway, by PD098059, or of the p38 MAPK pathway, by SB203580, blocked proliferation in response to IL-6. SB 203580 101-109 interleukin 6 Homo sapiens 148-152 10504489-11 1999 The role of these activations in IL-6 production was confirmed by the ability of both inhibitors SB203580 (1 to 30 microM) and PD98059 (0.01 to 10 microM) to inhibit basal and TNF-alpha-stimulated IL-6 production in both cell types. SB 203580 97-105 interleukin 6 Homo sapiens 197-201 34971958-10 2022 The p38 inhibitor SB203580 inhibited the secretion of IL-8, slightly inhibited the secretion of IL-6, and did not affect NF-kappaB activity. SB 203580 18-26 interleukin 6 Homo sapiens 96-100 10385244-10 1999 MK-571 mediated upregulation of IL-6 in the presence of IL-1 was partially attenuated by SB203580 and PD98059. SB 203580 89-97 interleukin 6 Homo sapiens 32-36 9733787-4 1998 SB203580 concentration-dependently inhibited protein production and gene expression of IL-6 by human FLSs. SB 203580 0-8 interleukin 6 Homo sapiens 87-91 9733787-6 1998 SB203580 significantly reduced the stability of IL-6 mRNA without affecting the rate of IL-6 gene transcription. SB 203580 0-8 interleukin 6 Homo sapiens 48-52 9120270-3 1997 SB 203580 significantly inhibited IL-1-stimulated IL-6, (30 to 50% at 1 microM) but not IL-8 production from human fibroblasts (gingival and dermal) and umbilical vein endothelial cells. SB 203580 0-9 interleukin 6 Homo sapiens 50-54 8617238-6 1996 Under the same conditions, SB203580 also completely inhibited TNF-induced synthesis of interleukin (IL)-6 and expression of a reporter gene that was driven by a minimal promoter containing two NF-Kappa B elements. SB 203580 27-35 interleukin 6 Homo sapiens 87-105 10358197-4 1999 IL-1-induced IL-6 production was also suppressed by SB203580. SB 203580 52-60 interleukin 6 Homo sapiens 13-17 9832620-8 1998 SB203580, a specific inhibitor of p38 MAP kinase, significantly inhibited IL-1beta-induced IL-6 and stromelysin-1 production by both parental FLSs and MH7A cells; although PD098059, an inhibitor of the p42/p44 MAP kinase pathway, did not affect it. SB 203580 0-8 interleukin 6 Homo sapiens 91-95 9452444-6 1998 We observed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 was able to repress TNF-stimulated expression of the IL-6 gene, as well as of a kappaB-dependent reporter gene construct, without affecting the levels of NF-kappaB binding to DNA. SB 203580 75-83 interleukin 6 Homo sapiens 137-141 33599317-13 2022 IL-6 induction was decreased by pretreatment of cells with NF-kappaB inhibitor SN50 or p38 MAPK inhibitor SB203580, while CCL2 induction was reduced by SN50 or JNK inhibitor SP600125. SB 203580 106-114 interleukin 6 Homo sapiens 0-4 34804428-15 2021 SB203580, PDTC, and alpha-LA reversed the effects of chemerin, reducing IL-6, TNF-alpha, NF-kappaB p-p65, and TGF-beta expression. SB 203580 0-8 interleukin 6 Homo sapiens 72-76 34171447-10 2021 Moreover, inactivation of p38MAPK with specific inhibitor (SB203580) attenuated IL-6 induced NED of LNCaP cells. SB 203580 59-67 interleukin 6 Homo sapiens 80-84 33441226-5 2021 Then, in the 16HEB cells stimulated by STAT3 inhibitor Stattic or p38 MAPK inhibitor SB203580 in combination with HDM, the mRNA and protein expression levels of IL-6 and IL-8 were detected by qPCR and CBA. SB 203580 85-93 interleukin 6 Homo sapiens 161-165 33355843-13 2021 On its own, SB203580 did not stimulate IL-6 secretion from HFCs; however, it dramatically suppressed the degree of IL-6 release stimulated by TNF-alpha from HFCs. SB 203580 12-20 interleukin 6 Homo sapiens 115-119 33441226-8 2021 Interestingly, while SB203580 inhibited the activation of p38 MAPK signaling pathway, it only inhibited the mRNA levels of IL-6 and IL-8 in HDM-induced 16HBE cells, but had no effect on their protein levels. SB 203580 21-29 interleukin 6 Homo sapiens 123-127 32500755-9 2021 RESULTS: Naringin or SB203580 pretreatment significantly suppressed the secretion of TNF-alpha and IL-6 induced by titanium particles in fibroblasts, while inhibition of ERK or JNK pathways showed no effect on production of TNF-alpha and IL-6. SB 203580 21-29 interleukin 6 Homo sapiens 99-103 32500755-9 2021 RESULTS: Naringin or SB203580 pretreatment significantly suppressed the secretion of TNF-alpha and IL-6 induced by titanium particles in fibroblasts, while inhibition of ERK or JNK pathways showed no effect on production of TNF-alpha and IL-6. SB 203580 21-29 interleukin 6 Homo sapiens 238-242 31322196-5 2019 The expression levels of interleukin (IL)-6, IL-8 and monocyte chemoattractant protein-1 increased following treatment with S100A8 and S100A9, and the increase was significantly blocked by specific signaling pathway inhibitors, including toll-like receptor 4 inhibitor (TLR4i), rottlerin, PD98059, SB203580 and BAY-11-7085. SB 203580 298-306 interleukin 6 Homo sapiens 25-43 32069432-6 2020 MCP-1 and GM-CSF levels, as well as gene expressions of IL-6 and IL-8 in HTR8/SVneo cells were greatly increased by TNF-alpha (5, 10 and 20 ng/mL), but reversed by sevoflurane and SB203580. SB 203580 180-188 interleukin 6 Homo sapiens 56-60 30404019-6 2019 ATP-induced IL-6 production was significantly inhibited by p38 inhibitors, SB203580, and doramapimod. SB 203580 75-83 interleukin 6 Homo sapiens 12-16 30404019-7 2019 Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 receptor trans-signaling was inhibited by kaempferol and SB203580. SB 203580 128-136 interleukin 6 Homo sapiens 61-65 30838176-8 2019 In line with these results, ERK (U0126) and p38 MAPK (SB203580) specific signaling inhibitors suppressed hIL-6 expression and attenuated cell growth in PEL cells. SB 203580 54-62 interleukin 6 Homo sapiens 105-110 30022772-7 2018 The gamma-irradiation-induced increase in IL-6 and IL-8 production was suppressed by apyrase (ecto-nucleotidase), NF157 (selective P2Y11 receptor antagonist) and SB203580 (p38 MAPK inhibitor). SB 203580 162-170 interleukin 6 Homo sapiens 42-46 30174670-10 2018 Both inhibition of p38 MAPK by SB203580 (10 microM) and knockdown of ER stress effector CCAAT-enhancer-binding protein homologous protein (CHOP) reduced gene and protein expression of IL-6 in Tg-treated cells. SB 203580 31-39 interleukin 6 Homo sapiens 184-188 29193446-10 2018 p38MAPK inhibitor SB203580 reduced the development of senescence and IL-6 by TNF-alpha and LPS. SB 203580 18-26 interleukin 6 Homo sapiens 69-73 29245047-6 2018 Conversely, pretreatment with SB203580, a selective inhibitor of p38 MAPK, blocked p38 MAPK phosphorylation and IL-6 and IL-8 expression. SB 203580 30-38 interleukin 6 Homo sapiens 112-116 30116631-11 2018 More importantly, the effect of MG132 on upregulating the levels of IL-6 was inhibited by SB203580, an inhibitor of P38 MAP kinases. SB 203580 90-98 interleukin 6 Homo sapiens 68-72 29412148-6 2018 A specific inhibitor of p38MAPK, SB203580 significantly decreased the secretion of IL-6 and IL-8, the major components of SASPs. SB 203580 33-41 interleukin 6 Homo sapiens 83-87 29061842-8 2018 Inhibition of p38 with SB203580 prevented IL-6 production, without altering permeability. SB 203580 23-31 interleukin 6 Homo sapiens 42-46